Haura EB - Search Results

1

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.

Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Creelan BC, et al. Among authors: haura eb. Nat Med. 2021 Aug;27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385708 Free PMC article. Clinical Trial.

2

Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.

Haura EB. Haura EB. Cancer Control. 2001 Jul-Aug;8(4):326-36. doi: 10.1177/107327480100800404. Cancer Control. 2001. PMID: 11483886 Free article. Review.

3

Management of advanced non-small cell lung cancer: current trends.

Haura EB. Haura EB. Curr Opin Pulm Med. 2002 Jul;8(4):251-6. doi: 10.1097/00063198-200207000-00002. Curr Opin Pulm Med. 2002. PMID: 12055385 Review.

4

Gene therapy for lung cancer. An introduction.

Haura EB, Sotomayor E, Antonia SJ. Haura EB, et al. Methods Mol Med. 2003;75:529-43. doi: 10.1385/1-59259-324-0:529. Methods Mol Med. 2003. PMID: 12407762 Review.

5

Gene therapy for lung cancer.

Haura EB, Sotomayor E, Antonia SJ. Haura EB, et al. Mol Biotechnol. 2003 Oct;25(2):139-48. doi: 10.1385/MB:25:2:139. Mol Biotechnol. 2003. PMID: 14526124 Review.

6

Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution.

Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Simon GR, et al. Cancer Control. 2003 Sep-Oct;10(5):388-95. doi: 10.1177/107327480301000506. Cancer Control. 2003. PMID: 14581894 Free article. Clinical Trial.

7

Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.

Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Chiappori A, et al. Oncology. 2005;68(4-6):382-90. doi: 10.1159/000086979. Epub 2005 Jul 12. Oncology. 2005. PMID: 16020967 Review.

8

Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.

Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Haura EB, et al. Clin Cancer Res. 2005 Dec 1;11(23):8288-94. doi: 10.1158/1078-0432.CCR-05-0827. Clin Cancer Res. 2005. PMID: 16322287

9

DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. Zheng Z, et al. N Engl J Med. 2007 Feb 22;356(8):800-8. doi: 10.1056/NEJMoa065411. N Engl J Med. 2007. PMID: 17314339 Free article.

10

Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.

de Lima Lopes G Jr, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. de Lima Lopes G Jr, et al. Cancer. 2007 Apr 1;109(7):1413-9. doi: 10.1002/cncr.22522. Cancer. 2007. PMID: 17326096 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

240 results

Search Page